Do analysts recommend MRVI or AMRN?

Maravai LifeSciences currently has a consensus price target of $5.50, suggesting a potential downside of 11.86%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media favor MRVI or AMRN?

In the previous week, Amarin had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 6 mentions for Amarin and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.62 beat Amarin's score of 0.58 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AMRN or PURR?

Hyperliquid Strategies has a consensus price target of $9.25, indicating a potential upside of 17.53%. Given Hyperliquid Strategies' higher probable upside, analysts clearly believe Hyperliquid Strategies is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Hyperliquid Strategies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to AMRN or PURR?

In the previous week, Amarin had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 6 mentions for Amarin and 3 mentions for Hyperliquid Strategies. Amarin's average media sentiment score of 0.58 beat Hyperliquid Strategies' score of 0.30 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AMRN or IMTX?

Immatics has a consensus target price of $20.80, indicating a potential upside of 105.33%. Given Immatics' stronger consensus rating and higher possible upside, analysts plainly believe Immatics is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Immatics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has higher valuation & earnings, AMRN or IMTX?

Amarin has higher revenue and earnings than Immatics. Amarin is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.56 -$38.80M -$0.65 N/A Immatics $54.60M 24.87 -$222.26M -$1.99 N/A

Is AMRN or IMTX more profitable?

Amarin has a net margin of -15.51% compared to Immatics' net margin of -572.35%. Amarin's return on equity of -2.99% beat Immatics' return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% Immatics -572.35% -47.36% -39.35%

Do analysts prefer AMRN or PAHC?

Phibro Animal Health has a consensus target price of $42.50, indicating a potential upside of 35.35%. Given Phibro Animal Health's higher probable upside, analysts clearly believe Phibro Animal Health is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Phibro Animal Health 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to AMRN or PAHC?

In the previous week, Amarin had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for Amarin and 5 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.99 beat Amarin's score of 0.58 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amarin (AMRN) Competitors

$15.94 +0.02 (+0.13%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$15.97 +0.03 (+0.19%)

As of 06/30/2026 04:10 PM Eastern

Compare

AMRN vs. MRVI, PURR, IMTX, DMRA, and PAHC

Should you buy Amarin stock or one of its competitors? MarketBeat compares Amarin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amarin include Maravai LifeSciences (MRVI), Hyperliquid Strategies (PURR), Immatics (IMTX), Damora Therapeutics, Inc. Common Stock (DMRA), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.

How does Amarin compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Maravai LifeSciences currently has a consensus price target of $5.50, suggesting a potential downside of 11.86%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amarin has a net margin of -15.51% compared to Maravai LifeSciences' net margin of -51.07%. Amarin's return on equity of -2.99% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Amarin	-15.51%	-2.99%	-2.07%

In the previous week, Amarin had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 6 mentions for Amarin and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.62 beat Amarin's score of 0.58 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amarin has higher revenue and earnings than Maravai LifeSciences. Amarin is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.67	-$130.77M	-$0.71	N/A
Amarin	$213.65M	1.56	-$38.80M	-$0.65	N/A

Maravai LifeSciences has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Amarin has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Summary

Amarin beats Maravai LifeSciences on 11 of the 17 factors compared between the two stocks.

How does Amarin compare to Hyperliquid Strategies?

Amarin (NASDAQ:AMRN) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Hyperliquid Strategies has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

In the previous week, Amarin had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 6 mentions for Amarin and 3 mentions for Hyperliquid Strategies. Amarin's average media sentiment score of 0.58 beat Hyperliquid Strategies' score of 0.30 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.3% of Amarin shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Hyperliquid Strategies has a consensus price target of $9.25, indicating a potential upside of 17.53%. Given Hyperliquid Strategies' higher probable upside, analysts clearly believe Hyperliquid Strategies is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Amarin has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Hyperliquid Strategies has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.56	-$38.80M	-$0.65	N/A
Hyperliquid Strategies	$1M	1,136.82	-$16.01M	-$7.37	N/A

Summary

Amarin and Hyperliquid Strategies tied by winning 8 of the 16 factors compared between the two stocks.

How does Amarin compare to Immatics?

Amarin (NASDAQ:AMRN) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

22.3% of Amarin shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amarin has higher revenue and earnings than Immatics. Amarin is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.56	-$38.80M	-$0.65	N/A
Immatics	$54.60M	24.87	-$222.26M	-$1.99	N/A

Immatics has a consensus target price of $20.80, indicating a potential upside of 105.33%. Given Immatics' stronger consensus rating and higher possible upside, analysts plainly believe Immatics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Amarin has a net margin of -15.51% compared to Immatics' net margin of -572.35%. Amarin's return on equity of -2.99% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Immatics	-572.35%	-47.36%	-39.35%

Amarin has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Immatics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

In the previous week, Amarin had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Amarin and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Amarin's score of 0.58 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Positive
Immatics	Very Positive

Summary

Amarin beats Immatics on 9 of the 17 factors compared between the two stocks.

How does Amarin compare to Damora Therapeutics, Inc. Common Stock?

Amarin (NASDAQ:AMRN) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.43, indicating a potential upside of 63.12%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Amarin has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Amarin has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Amarin is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.56	-$38.80M	-$0.65	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

In the previous week, Amarin had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Amarin and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.89 beat Amarin's score of 0.58 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Positive
Damora Therapeutics, Inc. Common Stock	Very Positive

22.3% of Amarin shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Amarin and Damora Therapeutics, Inc. Common Stock tied by winning 8 of the 16 factors compared between the two stocks.

How does Amarin compare to Phibro Animal Health?

Amarin (NASDAQ:AMRN) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Phibro Animal Health has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.56	-$38.80M	-$0.65	N/A
Phibro Animal Health	$1.30B	0.98	$48.26M	$2.33	13.48

Phibro Animal Health has a net margin of 6.35% compared to Amarin's net margin of -15.51%. Phibro Animal Health's return on equity of 37.14% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Phibro Animal Health	6.35%	37.14%	8.57%

In the previous week, Amarin had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for Amarin and 5 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.99 beat Amarin's score of 0.58 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a consensus target price of $42.50, indicating a potential upside of 35.35%. Given Phibro Animal Health's higher probable upside, analysts clearly believe Phibro Animal Health is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amarin has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Phibro Animal Health beats Amarin on 12 of the 17 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRN vs. The Competition

Export

Metric	Amarin	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$333.83M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-24.52	20.90	27.25	24.87
Price / Sales	1.56	341.80	543.53	102.84
Price / Cash	44.10	143.77	48.53	58.59
Price / Book	0.72	8.75	10.93	6.54
Net Income	-$38.80M	$23.81M	$3.57B	$336.70M
7 Day Performance	-2.96%	3.60%	2.31%	2.88%
1 Month Performance	11.00%	3.72%	1.39%	0.64%
1 Year Performance	-5.18%	68.80%	36.73%	31.34%

Amarin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRN Amarin	1.6854 of 5 stars	$15.94 +0.1%	N/A	-1.7%	$333.83M	$213.65M	N/A	360	News Coverage
MRVI Maravai LifeSciences	1.6548 of 5 stars	$5.25 +1.0%	$5.50 +4.8%	+158.9%	$1.34B	$185.74M	N/A	610	Positive News
PURR Hyperliquid Strategies	2.1124 of 5 stars	$9.20 -0.9%	$9.25 +0.5%	N/A	$1.34B	$1M	N/A	N/A	Short Interest Increase
IMTX Immatics	2.7294 of 5 stars	$9.78 flat	$20.80 +112.7%	+88.3%	$1.31B	$54.60M	N/A	260	Positive News
DMRA Damora Therapeutics, Inc. Common Stock	3.8226 of 5 stars	$23.89 +12.5%	$42.43 +77.6%	+662.8%	$1.31B	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRN) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amarin (AMRN) Competitors

AMRN vs. MRVI, PURR, IMTX, DMRA, and PAHC

How does Amarin compare to Maravai LifeSciences?

Summary

How does Amarin compare to Hyperliquid Strategies?

Summary

How does Amarin compare to Immatics?

Summary

How does Amarin compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Amarin compare to Phibro Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amarin (AMRN) Competitors

AMRN vs. MRVI, PURR, IMTX, DMRA, and PAHC

How does Amarin compare to Maravai LifeSciences?

Do analysts recommend MRVI or AMRN?

Do institutionals and insiders have more ownership in MRVI or AMRN?

Is MRVI or AMRN more profitable?

Does the media favor MRVI or AMRN?

Which has preferable earnings and valuation, MRVI or AMRN?

Which has more volatility & risk, MRVI or AMRN?

Summary

How does Amarin compare to Hyperliquid Strategies?

Is AMRN or PURR more profitable?

Does the media refer more to AMRN or PURR?

Do institutionals & insiders believe in AMRN or PURR?

Do analysts rate AMRN or PURR?

Which has more volatility & risk, AMRN or PURR?

Which has better earnings & valuation, AMRN or PURR?

Summary

How does Amarin compare to Immatics?

Do institutionals and insiders believe in AMRN or IMTX?

Which has higher valuation & earnings, AMRN or IMTX?

Do analysts rate AMRN or IMTX?

Is AMRN or IMTX more profitable?

Which has more risk and volatility, AMRN or IMTX?

Does the media refer more to AMRN or IMTX?

Summary

How does Amarin compare to Damora Therapeutics, Inc. Common Stock?

Do analysts prefer AMRN or DMRA?

Which has more volatility & risk, AMRN or DMRA?

Which has preferable earnings & valuation, AMRN or DMRA?

Is AMRN or DMRA more profitable?

Does the media refer more to AMRN or DMRA?

Do institutionals & insiders believe in AMRN or DMRA?

Summary

How does Amarin compare to Phibro Animal Health?

Which has stronger valuation & earnings, AMRN or PAHC?

Is AMRN or PAHC more profitable?

Does the media refer more to AMRN or PAHC?

Do analysts prefer AMRN or PAHC?

Which has more volatility and risk, AMRN or PAHC?

Do insiders & institutionals believe in AMRN or PAHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools